Plasmonic polyaniline/gold nanorods hybrid composites for selective NIR photodetection: Synthesis and characterization

Abstract In this study, we present the development of polyaniline/gold nanorod nanocomposites and the effect of the nanorods' aspect ratio and concentration on the overall electrical conductivity of nanocomposite systems. The electrical characterization showed that at the same atomic gold concentration, the conductivity of the nanocomposites increased by about 14% after increasing the gold nanorods' aspect ratio from 2.9 to 3.8. Furthermore, the conductivity of the nanocomposites increases linearly with the concentration of atomic gold, keeping the nanorods' aspect ratio stable, due to increasing the metallic content. The interaction between polyaniline and gold nanorods was investigated by FTIR, micro Raman, and XPS spectroscopic techniques, indicating the delocalization of the charges across the polymer chains induced by the incorporation of the nanorods. The interaction most likely occurs through the imine nitrogen of the polymer's backbone. The homogenous distribution of the gold nanorods in the polyaniline matrix was verified by TEM. Furthermore, the selective photosensitivity of the developed nanocomposites to NIR light was examined, and an increase in their current density was detected when the nanocomposites were irradiated at the wavelength that coincides with the longitudinal plasmonic resonance absorption of the incorporated nanorods. We foresee applications of the developed nanocomposites in numerous optoelectronic sectors

A new tool for the assessment of the development of students' mathematical competencies

publishedVersionNivå

Mechanical reinforcement and water repellency induced to cellulose sheets by a polymer treatment

The present study reports a simple method to control the mechanical and surface properties of cellulose fiber networks and to protect them from humidity, without altering their initial morphology. This is achieved by dip coating the fiber networks in solutions containing different amounts of ethyl cyanoacrylate monomer (ECA). Under ambient humidity and due to the presence of the -OH groups of the cellulose, the ECA polymerizes around each individual cellulosic fiber forming a thin poly(ethyl cyanoacrylate) (PECA) shell. PECA was found to interact with the cellulose surface via hydrogen bonding as evidenced by Fourier transform infrared spectroscopy and thermogravimetric analysis measurements. The detailed surface characterization reveals that only 3.5 wt% of ECA in solution is sufficient to form compact PECA cladding around every cellulose fiber. After the proposed treatment the cellulose sheets become hydrophobic, well protected from the environmental humidity and with increased Young's modulus

Prognostic value of follicular fluid 25-OH vitamin D and glucose levels in the IVF outcome

Objectives: The aim of the present study was to measure serum and follicular fluid 25-OH vitamin D and glucose levels in women who underwent IVF-ET treatment and to further investigate whether the circulating 25-OH vitamin D and glucose levels correlate with IVF success. Methods: This prospective observational study included 101 consecutive women who underwent 101 IVF-ICSI ovarian stimulation cycles and were allocated to one of the three groups according to their follicular fluid 25-OH vitamin D concentrations. Group A (n = 31) with less than 20 ng/ml, group B (n = 49) with vitamin levels between 20.1 and 30 ng/ml and group C (n = 21) with more than 30 ng/ml vitamin concentration. Results: Follicular fluid vitamin levels significantly correlated with the quality of embryos in total (r = -0.27, p = 0.027), while the quality of embryos of group C were of lower quality as compared to those of groups A and B (p = 0.009). Follicular fluid glucose levels were lower in women of group C as compared to the respective levels of groups A and B (p = 0.003). Clinical pregnancy rate demonstrated in 14.5% in women of group C and 32.3% and 32.7% in groups A and B, respectively (p = 0.047). Conclusion: The data suggests that excess serum and follicular fluid vitamin levels in combination with decreased follicular fluid glucose levels have a detrimental impact on the IVF outcome

Reporting of adverse events of treatment interventions in multiple myeloma: an overview of systematic reviews

The present study is an overview of systematic reviews focusing on adverse events of antimyeloma treatments. It provides a systematic description of adverse events as they are reported in the systematic reviews as well as a critical appraisal of included reviews. We conducted a comprehensive literature search in the most widely used electronic databases looking for systematic reviews that had an adverse event of an antimyeloma treatment intervention as primary outcome. Two independent reviewers conducted selection of included studies and data extraction on predesigned online forms and assessed study quality using AMSTAR 2. Overall corrected covered area (CCA) was calculated to examine the overlap of primary studies across systematic reviews. After screening eligible studies, 23 systematic reviews were included in this overview. Seven reviews with overall CCA of 14.7% examined cardiovascular adverse events of different drugs, including immunomodulatory drugs and proteasome inhibitors (mainly carfilzomib). Nine focused on infections, presenting with overall CCA of 5.8%, each one focused on a different drug or drug class. Three studied thromboembolism in patients treated either with lenalidomide, any immunomodulatory drug, or with daratumumab and had an overall CCA equal to 1.5%. Four more reviews focused on bortezomib-associated neurotoxicity, carfilzomib-associated renal toxicity, or second primary malignancies as an adverse event of lenalidomide or anti-CD38 monoclonal antibody treatment. The quality of included studies as judged by AMSTAR 2 was mostly critically low. Absence of a priori registered protocol and formal assessment of risk of bias of included primary studies were the most common shortcomings. Reporting of antimyeloma drug-associated toxicity is supported by multiple systematic reviews; nevertheless, methodological quality of existing reviews is mostly low

Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials

Aims/hypothesis: We conducted a systematic review and network meta-analysis to compare the efficacy and safety of s.c. administered tirzepatide vs s.c. administered semaglutide for adults of both sexes with type 2 diabetes mellitus. Methods: We searched PubMed and Cochrane up to 11 November 2023 for RCTs with an intervention duration of at least 12 weeks assessing s.c. tirzepatide at maintenance doses of 5 mg, 10 mg or 15 mg once weekly, or s.c. semaglutide at maintenance doses of 0.5 mg, 1.0 mg or 2.0 mg once weekly, in adults with type 2 diabetes, regardless of background glucose-lowering treatment. Eligible trials compared any of the specified doses of tirzepatide and semaglutide against each other, placebo or other glucose-lowering drugs. Primary outcomes were changes in HbA1c and body weight from baseline. Secondary outcomes were achievement of HbA1c target of ≤48 mmol/mol (≤6.5%) or <53 mmol/mol (<7.0%), body weight loss of at least 10%, and safety outcomes including gastrointestinal adverse events and severe hypoglycaemia. We used version 2 of the Cochrane risk-of-bias tool (ROB 2) to assess the risk of bias, conducted frequentist random-effects network meta-analyses and evaluated confidence in effect estimates utilising the Confidence In Network Meta-Analysis (CINeMA) framework. Results: A total of 28 trials with 23,622 participants (44.2% female) were included. Compared with placebo, tirzepatide 15 mg was the most efficacious treatment in reducing HbA1c (mean difference −21.61 mmol/mol [−1.96%]) followed by tirzepatide 10 mg (−20.19 mmol/mol [−1.84%]), semaglutide 2.0 mg (−17.74 mmol/mol [−1.59%]), tirzepatide 5 mg (−17.60 mmol/mol [−1.60%]), semaglutide 1.0 mg (−15.25 mmol/mol [−1.39%]) and semaglutide 0.5 mg (−12.00 mmol/mol [−1.09%]). In between-drug comparisons, all tirzepatide doses were comparable with semaglutide 2.0 mg and superior to semaglutide 1.0 mg and 0.5 mg. Compared with placebo, tirzepatide was more efficacious than semaglutide for reducing body weight, with reductions ranging from 9.57 kg (tirzepatide 15 mg) to 5.27 kg (tirzepatide 5 mg). Semaglutide had a less pronounced effect, with reductions ranging from 4.97 kg (semaglutide 2.0 mg) to 2.52 kg (semaglutide 0.5 mg). In between-drug comparisons, tirzepatide 15 mg, 10 mg and 5 mg demonstrated greater efficacy than semaglutide 2.0 mg, 1.0 mg and 0.5 mg, respectively. Both drugs increased incidence of gastrointestinal adverse events compared with placebo, while neither tirzepatide nor semaglutide increased the risk of serious adverse events or severe hypoglycaemia. Conclusions/interpretation: Our data show that s.c. tirzepatide had a more pronounced effect on HbA1c and weight reduction compared with s.c. semaglutide in people with type 2 diabetes. Both drugs, particularly higher doses of tirzepatide, increased gastrointestinal adverse events. Registration: PROSPERO registration no. CRD42022382594 Graphical Abstract

Lunar impact flash results and space surveillance activities at Kryoneri Observatory

We present current and future activities regarding lunar impact flash and NEO observations and satellite tracking from Kryoneri Observatory. In particular, we present results from the ESA-funded NELIOTA program, which has been monitoring the Moon for impact flashes since early 2017. Using the 1.2 m Kryoneri telescope, which is equipped with two high frame-rate cameras recording simultaneously in two optical bands, NELIOTA has recorded over 170 validated lunar impact flashes, while another ~90 have been characterized as suspected. We present statistical results concerning the sizes, the masses and the appearance frequency of the meteoroids in the vicinity of the Earth, as well as the temperatures developed during the impacts. Moreover, we present the capabilities of the Kryoneri telescope as a sensor for satellite tracking and the future plans regarding the provision of high-quality services for both the Planetary Defense activities of ESA (S2P/PDO) and the European Union's Space Surveillance and Tracking programme (EU/SST).Comment: 14 pages, 19 figures. Proceedings of the 2nd NEO and Debris Detection Conference, Darmstadt, Germany, 24-26 January 202